Carregant...
Structural basis for ineffective T-cell responses to MHC anchor residue-improved “heteroclitic” peptides
MHC anchor residue-modified “heteroclitic” peptides have been used in many cancer vaccine trials and often induce greater immune responses than the wild-type peptide. The best-studied system to date is the decamer MART-1/Melan-A(26–35) peptide, EAAGIGILTV, where the natural alanine at position 2 has...
Guardat en:
| Publicat a: | Eur J Immunol |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BlackWell Publishing Ltd
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4357396/ https://ncbi.nlm.nih.gov/pubmed/25471691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/eji.201445114 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|